STRATEC Biomedical (SBS) Financial Statements

Compare

5 Followers

STRATEC Biomedical Financial Overview

STRATEC Biomedical's market cap is currently €215.16M. The company's EPS TTM is €; its P/E ratio is 58.01; and it has a dividend yield of 2.71%. STRATEC Biomedical is scheduled to report earnings on March 26, 2026, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 25	Dec 23	Dec 22	Dec 21	Mar 21
Income Statement
Total Revenue	€ 257.62M	€ 270.41M	€ 274.63M	€ 287.33M	€ 250.10M
Gross Profit	€ 76.39M	€ 68.16M	€ 79.49M	€ 87.71M	€ 68.99M
Operating Income	€ 28.18M	€ 28.12M	€ 42.00M	€ 49.63M	€ 32.48M
EBITDA	€ 47.34M	€ 43.16M	€ 57.53M	€ 66.52M	€ 56.72M
Net Income	€ 16.02M	€ 15.37M	€ 29.22M	€ 39.96M	€ 25.18M
Balance Sheet
Cash & Short-Term Investments	€ 48.73M	€ 34.22M	€ 24.07M	€ 48.72M	€ 39.15M
Total Assets	€ 445.06M	€ 466.58M	€ 397.50M	€ 368.52M	€ 331.90M
Total Debt	€ 130.53M	€ 141.37M	€ 87.15M	€ 85.30M	€ 109.58M
Net Debt	€ 83.37M	€ 107.84M	€ 64.48M	€ 38.11M	€ 72.02M
Total Liabilities	€ 202.53M	€ 233.25M	€ 172.32M	€ 162.77M	€ 159.36M
Stockholders' Equity	€ 242.53M	€ 233.33M	€ 225.18M	€ 205.76M	€ 172.54M
Cash Flow
Free Cash Flow	€ 30.52M	€ 2.00M	€ -8.74M	€ 43.24M	€ 6.27M
Operating Cash Flow	€ 48.71M	€ 19.43M	€ 10.28M	€ 63.47M	€ 31.85M
Investing Cash Flow	€ -15.97M	€ -44.16M	€ -19.00M	€ -20.13M	€ -21.84M
Financing Cash Flow	€ -20.30M	€ 35.44M	€ -14.11M	€ -34.33M	€ 5.22M

Currency in EUR

STRATEC Biomedical Earnings and Revenue History

Income Statement >

STRATEC Biomedical Debt to Assets

Balance Sheet >

STRATEC Biomedical Cash Flow

Cash Flow >

STRATEC Biomedical Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >